SB 1260 would update Missouri law on epinephrine access and allergy preparedness, and it would add a new child care facility allergy policy requirement. The bill repeals and reenacts section 196.990 to modernize terminology from “epinephrine auto-injector” to “epinephrine delivery device” and to allow physicians to prescribe, and authorized entities to stock, these devices for emergency use. Authorized entities include places where allergens may be present, such as restaurants, recreation camps, youth sports leagues, child care facilities, amusement parks, and sports arenas, but not public schools or public charter schools.
The bill also creates section 210.225, titled “Elijah’s Law,” requiring each licensed child care provider to adopt an allergy prevention and response policy by July 1, 2028. The policy must address building-wide, room-level, and individual allergy management, staff roles, confidentiality, coordination with state and local health authorities, and the use of individualized health plans or Section 504 plans where appropriate. The Department of Elementary and Secondary Education must develop model policy guidance by July 1, 2027.
SB 1260 would amend Missouri’s public health and child care statutes by expanding and clarifying the legal framework for stocking and using epinephrine delivery devices and by imposing a new statewide allergy-policy mandate on licensed child care providers. It would also extend liability protections for authorized entities, trained personnel, physicians, and trainers acting in good faith, while preserving exceptions for reckless or willful misconduct. In addition, basic life support ambulances and stretcher vans would be required to carry epinephrine delivery devices and have at least one trained staff member.
The bill appears generally supportive of allergy safety and emergency preparedness, with its structure suggesting a preventive public-health approach rather than a controversial policy change. The absence of committee transcripts and recorded votes limits direct evidence of debate, but the bill’s caption and provisions indicate a favorable orientation toward protecting children and other vulnerable individuals from anaphylaxis. Overall, the measure reads as a safety-focused bill likely to attract broad support from child care, health, and allergy-prevention advocates.
The main points of potential contention are operational and legal rather than ideological. Child care providers may be concerned about the cost and administrative burden of drafting policies, training staff, coordinating with health agencies, and managing confidentiality requirements. There may also be questions about the scope of liability protections, the requirement to notify emergency dispatch centers, and the rule that epinephrine generally may not be administered to minors without parental consent unless the child is in imminent danger and a parent or guardian is not present. Another possible issue is the bill’s exclusion of public schools and public charter schools from the definition of authorized entity in the epinephrine section, which may raise questions about consistency across child-serving institutions.